Shareholders filed a class action lawsuit against the company claiming it misrepresented the results of an inconclusive and limited study of its experimental drug AGI-1067. According to the Securities and Exchange Commission, plaintiffs voluntarily dismissed the actions. (Jul-15-05)
[ATLANTA BUSINESS JOURNAL]
Stay Informed
Get the latest on class action lawsuits, settlements & more! Subscribe to our free weekly newsletter.
Get our Newsletter!
Submit a New Complaint
Been wronged by a similar product or service?
Click here to send us your complaint.
